Author

Burak Zeybek

Yale University School of Medicine - Cited by 1,345 - Gynecologic Oncology

Biography

Burak Zeybek, MD is a doctor primarily located in NEW HAVEN, CT, with other offices in Galveston, TX and Galveston, TX,He has 16 years of experience. His specialties include Gynecologic Oncology, Obstetrics & Gynecology.
Title
Cited by
Year
Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy
L Zammataro, S Lopez, S Bellone, F Pettinella, E Bonazzoli, E Perrone, ...Proceedings of the National Academy of Sciences 116 (45), 22730-22736, 2019201
58
2019
Integrated mutational landscape analysis of uterine leiomyosarcomas
J Choi, A Manzano, W Dong, S Bellone, E Bonazzoli, L Zammataro, X Yao, ...Proceedings of the National Academy of Sciences 118 (15), e2025182118, 2021202
46
2021
Comparison of the long‐term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: a database study
AM Rodriguez, B Zeybek, M Vaughn, J Westra, S Kaul, JR Montealegre, ...Cancer 126 (8), 1656-1667, 2020202
43
2020
PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib
A Bianchi, S Lopez, G Altwerger, S Bellone, E Bonazzoli, L Zammataro, ...Gynecologic oncology 155 (1), 144-150, 2019201
33
2019
Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas
S Lopez, E Perrone, S Bellone, E Bonazzoli, B Zeybek, C Han, ...Oncotarget 11 (5), 560, 2020202
29
2020
Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan
B Zeybek, A Manzano, A Bianchi, E Bonazzoli, S Bellone, N Buza, P Hui, ...Scientific Reports 10 (1), 973, 2020202
28
2020
Preclinical activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) linked to the active metabolite of irinotecan …
E Perrone, S Lopez, B Zeybek, S Bellone, E Bonazzoli, S Pelligra, ...Frontiers in Oncology 10, 118, 2020202
28
2020
Immunotherapy in cervical cancer
D Mauricio, B Zeybek, J Tymon-Rosario, J Harold, AD SantinCurrent Oncology Reports 23, 1-12, 2021202
28
2021
Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies
BK Erickson, B Zeybek, AD Santin, AN FaderCurrent opinion in obstetrics & gynecology 32 (1), 57, 2020202
27
2020
A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability
S Bellone, DM Roque, ER Siegel, N Buza, P Hui, E Bonazzoli, ...Cancer 128 (6), 1206-1218, 2022202
25
2022
Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial …
E Perrone, P Manara, S Lopez, S Bellone, E Bonazzoli, A Manzano, ...Molecular Oncology 14 (3), 645-656, 2020202
23
2020
In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma
C Han, E Perrone, B Zeybek, S Bellone, J Tymon-Rosario, G Altwerger, ...Gynecologic Oncology 156 (2), 430-438,
20
2020
A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics …
S Bellone, DM Roque, ER Siegel, N Buza, P Hui, E Bonazzoli, ...Annals of Oncology 32 (8), 1045-1046, 2021202
19
2021
PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers
E Bonazzoli, E Cocco, S Lopez, S Bellone, L Zammataro, A Bianchi, ...Gynecologic oncology 153 (1), 158-164, 2019201
18
2019
Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu
J Tymon-Rosario, ER Siegel, S Bellone, J Harold, N Adjei, B Zeybek, ...Gynecologic oncology 163 (1), 93-99, 2021202
12
2021
Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based study
EM Webster, GS Yadav, S Gysler, B McNamara, J Black, J Tymon-Rosario, ...Gynecologic Oncology Reports 34, 0667, 2020202
10
2020
Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
D Roque, E Siegel, N Buza, S Bellone, DA Silasi, G Huang, V Andikyan, ...Gynecologic Oncology 162, S5, 2021202
8
2021
Financial toxicity in patients with gynecologic malignancies: a cross sectional study
B Zeybek, E Webster, N Pogosian, J Tymon-Rosario, A Balch, G Altwerger, ...Journal of Gynecologic Oncology 32 (6), 2021202
7
2021
DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo
J Tymon-Rosario, E Bonazzoli, S Bellone, A Manzano, S Pelligra, ...Gynecologic Oncology 163 (2), 334-341, 2021202
7
2021
Impact of timing on wound dressing removal after caesarean delivery: a multicentre, randomised controlled trial
GS Kilic, E Demirdag, MF Findik, OL Tapisiz, ME Sak, O Altinboga, S Sak, ...Journal of Obstetrics and Gynaecology 41 (3), 348-32, 2021202
5
2021

Referred From: https://scholar.google.com/citations?user=OCCb5lEAAAAJ&hl=en

Cited by
Citations 1345
h-index 24
i10-index 42
Recommended Journals
Open Access Journals